{"name":"Renovion, Inc.","slug":"renovion-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARINA-1","genericName":"ARINA-1","slug":"arina-1","indication":"Cystic fibrosis","status":"phase_3"}]}],"pipeline":[{"name":"ARINA-1","genericName":"ARINA-1","slug":"arina-1","phase":"phase_3","mechanism":"ARINA-1 is a small molecule inhaled cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","indications":["Cystic fibrosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQSmFmLURfN293bC15VkVib1FFbS1WNWhySnVPZEs5cXBjakpvSW8wZzVvQlUwZ0tIOFFOYlV0Yk9MdWFfeVpGTTJsMU15U3JxeTBJQ0R2cVNtOHp1VmRfaWFIMlk0NmttRm94bjBzRWFCYWwwSE5tajU5Rl9hYTZoQ0I5TUJic0NzSGN0Rnc2SzlyWVJmemR1X3UxZFYzSmd1b2RyRTBKTkRZdER2YkxTLWhadk5JLW5fQnNpZWNlaWFVeVI1cEJzQ2cteU9ZWGNLZjFqcURJRktPbS1SX3VJdUZvTXF0UTEyWVJNTGR2dnRCbnJuRWRxMk1uRUZaTGllRnkxZ0RMaGI1OHVPWVQ1dlE3Y19HSHB4N2c0TXJUZGpBX0tZSkVLLW15bUowQVFyZFotWDdkdy0zUTBmYjVxOVdteWVkalBmeUE?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Non-Cystic Fibrosis Bronchiectasis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barch","headline":"Non-Cystic Fibrosis Bronchiectasis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, Astr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPb0tiLTlxWUZNaHpRQ1puVTFqbnRpWHVranVyV2huU3dYRlNrbVlSSmZhellxZG1UVFYtS3piYVpoQUV6RGJyandKZzBkaUIwVE1NQ1oyQVJsdjhOX2V3NFlwTTZ2RTk4SnAxT0kyUWdwSkdvZ0QtUVJIVkpGS0ttc2wtMWM2UTNlcHZ2Z1JzcEJzb1hyVHlWWDVuUXhhbERsUHl4cVV6SnlTZmJhczRsV3MyZldOYm9JODZ0Ti1EWTVibjIwMnJTa1l1N09fc1JMdVpUU0JCQ0ZmVV9XMnhOcUJVQkVHakNIRmlYbEVpN0NEZVBWTVVsOE0wWncwTjJJYi1DbnBWZGdwa0YyM1pRbGh6NXZ6bjY2bDRjMnBFcEtPZEF5?oc=5","date":"2026-03-20","type":"pipeline","source":"Barchart.com","summary":"Cystic Fibrosis Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com","headline":"Cystic Fibrosis Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Insmed, AstraZeneca, Zambion, The Mar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2hMczZSNm9ka1BJdWgtbEQxSlh4MS1oNUt1Z0tvdEVWT0FMalk4Y25OQjJEb1hKUFRuUHRZblB1ZzdJSUMtZHhZMTBQTVVtNS1uSzdyUVh3SU4zOS1JMEZfcnFVTm5oY1c2WGRfaXdYSGZXRTgtdmRieWhtMWlOeFNMOFN3WFFyUGNQLUhEcXh4a0JtZVlKLTFoVUxtNjVubmRZVkEwcnh3MHVyM0d4Z3lBRER3Yy1tZGIzaFdkbGV1VE5MS0Z1NmhFNW8xSWNnUzdSekUwUjdfWkZMTUc3UkxOVWlhaktYeFVkVFlsemJqeDFUbU05c0hzLTRTODN1dzdQanpRSmpSazNOZHdWMzZB?oc=5","date":"2025-08-25","type":"pipeline","source":"GlobeNewswire","summary":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight - GlobeNewswire","headline":"Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNOUM0YWhXbFZrWmlLV2pweVJQS0Q4Y0U3QVQ4V2NTNm9kUDJYWEZCdGhrX1dTRFo0LTYyNWlsNHBwQTgtSWZBZjJ3eW9rX3R2NTJkOXRtY1dlUlc5Y0xndFdFVnlYSmd4NzJia3MzTG95OUEyX2tOa2VPRUtUTWJqRWNDY25VREJVU3JKRmpMM3RhUWRMV0xWVFEyQ3cwRVNGcHZOdnhaOXlBMlpGZXRfaGg3WDl6ZDE5T1ZCbVBfNDRJeUhQUWVqeUJhNlB4X0ZaMGh4Q25hVUN0STcyU2FlckJSbHFDM0FFaWRZU0VsQnpCM3VZZjc2d2VrSmZPWkRsU05IWmNHM2JLblNUTlhtWFJUYnZNVU9VS2RwUVFONEVlNFZVOThn?oc=5","date":"2025-01-27","type":"pipeline","source":"BioSpace","summary":"Bronchiectasis Market Size to Reach USD 766.7 Million by 2035, Impelled by Advancements in Diagnostic Improvements and the Escalating Incidence of Bronchiectasis. - BioSpace","headline":"Bronchiectasis Market Size to Reach USD 766.7 Million by 2035, Impelled by Advancements in Diagnostic Improvements and t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxQbHVQVGNLNTFfUHhJR0dZZUxacTk5eVI1TnpHX0p1cnVCOVJzWGVweWs1MDFaNXk1dUZpTXlHNGV1emppS3RXa3llSno2eTlxTUhITDYyQkV3dEtQallScldQZ25aNm9BN1ctc25zeWpSMG5ITE5MenY1U0E2Z1BqWGdTZVF5SFZCYkZIQzRUQVctZkt4cGtRTGF6U1BCbE1ra0pjZ2tFQ2JtTEtDdkpQVVdQNW8yY2xadmVrazBydmtWdFBHaUFrWXVNWDVlMXV0YkNQbGlJdFVLRWI0Sk1haHhlelB5dkNCRkFWRmdlZE9RNEtzMzBCUXhFank5TG92R3hnT3ZkU0pYeUk3S0V1a3RvVDRJNmR1YnE5X2p0b181V3ljNkFJamdlV3FjX1I5X1JyT0pxU2c?oc=5","date":"2024-11-13","type":"pipeline","source":"GlobeNewswire","summary":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over - GlobeNewswire","headline":"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-02-29","type":"pipeline","source":"GlobeNewswire","summary":"Bronchiolitis Obliterans Syndrome Market to Grow - GlobeNewswire","headline":"Bronchiolitis Obliterans Syndrome Market to Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOUWdmRHluU0I4a1I3RElBMVZzVTlobllaSU91N3RSeDRpTGtuejduNFZ5VGg2eUVWWlNfck9aQkdhNkdiSU5EV0FZeHY0OFNfTnJ0X1NmbTFpWkJWRV9mRW5sTzN5UnZkTTlPUjdKc0JJajZ3ZnpjZk01V1pBTUlWS3N5NVI2V0dscWU1N09aZ2NHanlna3U0QzNjZw?oc=5","date":"2023-09-21","type":"pipeline","source":"The Business Journals","summary":"2023 Corporate Leadership Awards: Carolyn Durham with Renovion - The Business Journals","headline":"2023 Corporate Leadership Awards: Carolyn Durham with Renovion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQQ1ktWjFYbkRJNWpFSml3MXhOdm8zTnFWekFaYjhTRVNjTHpESnp1djBGbmhMaW5uTFhaaEd3OHZEdTRuaUI3OWxnZTlGRS1KS250VzhaUFFYSDdiNzktZUZJMzdMM1EwTTFzcnF1c2dZTHhld2hDSF9na1RUZUk4cFlPTzVQUFhIWXlPTHNoZ00wY3BjY2tKY2I4NlpOTFVtUk44dWhzWEhrSVY4RWs5ZjUxNjliTkdjTG9xU2RvaXp4dThqYzhj?oc=5","date":"2023-06-12","type":"trial","source":"Northern Kentucky Tribune","summary":"CTI announces partner Renovion's first patient enrolled in phase three clinical trial for ARINA-1 - Northern Kentucky Tribune","headline":"CTI announces partner Renovion's first patient enrolled in phase three clinical trial for ARINA-1","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}